Apimeds Pharmaceuticals US, Inc (APUS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.14M | -3.82M | -1.73M | -3.36M | -20.31K | -99.62K | -186.75K | -184.06K | -263.1K | -340.57K | -272.5K | -19.95K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -10448.55% | -3732.92% | -824.29% | -1726.14% | 92.28% | 70.75% | 31.47% | - | - | -1606.71% | - | - |
| Net Income | -35.06M | -1.16M | -1.78M | -2.66M | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -74.59K |
| Depreciation & Amortization | 20.04K | 3.98K | 1.49K | 232 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 114.17K | 0 | 42.67K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 48.39K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 30.92M | -2.09M | -6.56K | 1.91M | 38.03K | 36.05K | 32.64K | 22.12K | 26.91K | 13.48K | 8.09K | 8.41K |
| Working Capital Changes | 1.86M | -578.1K | 17.48K | -2.6M | 344.05K | 175.97K | 113.13K | 243.19K | 6.46K | 212.91K | -170.57K | -2.15K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 490.61K | -10.02M | -22.54K | -13.37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | -9.39K | -21.42K | -22.54K | -13.37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 995K | 8.49M | 0 | 11.86M | 267.2K | 76.5K | 150K | 100K | 0 | 0 | 1.02M | 282.9K |
| Debt Issued (Net) | 995K | 9.05M | 0 | 0 | 250K | 0 | 150K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | -323.32K | 0 | 11.95M | 0 | 0 | 0 | 0 | 0 | 555K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -238.1K | 0 | -93.6K | 17.2K | 76.5K | 150K | 100K | 0 | -555K | 1.02M | 282.9K |
| Net Change in Cash | -657.12K | 2.65M | -1.75M | 8.48M | 246.89K | -23.12K | -36.76K | -84.06K | -263.1K | -340.57K | 750.6K | 262.94K |
| Free Cash Flow | -2.15M | -3.84M | -1.75M | -3.37M | -20.31K | -99.62K | -186.75K | -184.06K | -263.1K | -340.57K | -272.5K | -19.95K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -10494.79% | -3754.43% | -836.37% | -1733.4% | 92.28% | 70.75% | 31.47% | - | - | -1606.71% | - | - |
| FCF per Share | -0.14 | -0.35 | -1.39 | -3.25 | -0.02 | -0.08 | -0.15 | -0.15 | -0.21 | -0.27 | -0.21 | -0.02 |
| FCF Conversion (FCF/Net Income) | 0.06x | 3.30x | 0.97x | 1.26x | 0.05x | 0.32x | 0.56x | 0.41x | 0.89x | 0.60x | 2.48x | 0.27x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |